Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 101Specimen Handling 82pembrolizumab 78enzalutamide 63Nivolumab 60Gemcitabine 54Docetaxel 52apalutamide 42Radiosurgery 41Abiraterone Acetate 40Prednisone 39Androgen Antagonists 39Biopsy 37darolutamide 36Cisplatin 35cabozantinib 33Radiotherapy 32Carboplatin 29Pluvicto 28enfortumab vedotin 27abiraterone 27Ipilimumab 25Radiation 23durvalumab 22atezolizumab 22Leuprolide 20olaparib 19X-Rays 19Standard of Care 18avelumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
XRP6258 × Genitourinary × 90 days × Clear all
NCT04592237 2026-06-12

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
120 enrolled
Genitourinary

Prostatic Neoplasms

NCT03419234 2026-06-03

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
223 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡